Dr. Tomoko Ueda

Pathologist · Osaka University Hospital · Japan (JP) · Oncology

Tier 2STK-0017GoodOwner MSL MTMei Tanaka

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Thoracic oncology
Disease interests: NSCLC
Scientific interests: PD-L1 biomarkers
Engagement preference: In person
Advisory boards: 1
Publications: 15
Source system: Veeva CRM
Data quality: Good

Engagement plan

Cadence target for Tier 2: 2 per year (assumption)

Last engaged: 13 Sept 2026 (2 days ago)
Next planned contact: 15 Mar 2027
Last 6 months vs target: 100%
1 of 1 expected engagements

Insights from this stakeholder (1)

INS-0060PD-L1 testing turnaround
13 Sept 2026 · Diagnosis and screening
CriticalQuality review

Engagement history (1)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
13 Sept 2026	Scientific exchange	In person	Mei Tanaka	Vantrexa	PD-L1 testing turnaround	1	—	Submitted	ENG-0003

Timeline

13 Sept 2026
Scientific exchange
PD-L1 testing turnaround

Related stakeholders (9)

Osaka University Hospital

Dr. Javier Weber
Pathologist
Tier 3
Dr. Noor Dubois
Thoracic medical oncologist
Tier 3
Dr. Yuki Quinn
Thoracic medical oncologist
Tier 2
Dr. Ximena Rossi
Radiation oncologist
Tier 1
Dr. Benedikt Ivanova
Oncology pharmacist
Tier 2
Dr. Chloé Dubois
Pathologist
Tier 3
Dr. Farah Jensen
Primary care physician
Tier 1
Dr. Ximena Bauer
General neurologist
Tier 3
Dr. Andrea Fischer
General neurologist
Tier 2